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Synthesis of novel benzo[4,5]imidazo[1,2-a]pyrimido[4,5-d] pyrimidines 5/6 has been achieved by reaction of 2-amino-
4-aryl-4,10-dihydrobenzo[4,5]imidazo[1,2-a]pyrimidine-3-carbonitriles 4 with formaldehyde/urea. The key intermediate 4, 
is obtained by reaction of 2-aminobenzaldehyde 1 with aromatic aldehyde and malononitrile by a three-component one-pot 
process. The newly synthesized title compounds 5/6 have been evaluated for their in vitro antimicrobial activity. 
Compounds 5 and 6 exhibit potent antimicrobial activity compared to that of standard drugs. 
Keywords: Multi-component reaction, benzo[4,5]imidazo[1,2-a]pyrimidine-3-carbonitriles, cyclization, 
benzo[4,5]imidazo[1,2-a]pyrimido[4,5-d]pyrimidines, antimicrobial activity 
Multi-component reactions (MCRs) play an important 
role in organic and medicinal chemistry1 as it 
furnishes products with a high degree of  
structural variability. MCRs are inexpensive, less 
time-consuming and eco-friendly in comparison to 
conventional multi-step synthesis2,3. The exploitation 
of a simple molecule with different functionalities for 
the synthesis of bio heterocycles is a useful 
contribution in the heterocyclic chemistry4. 
Heterocyclic moieties play a prominent role in the 
design and synthesis of bioactive molecules. 
Pyrimidines and fused pyrimidines have been found 
to possess diverse biological activity5-7. In particular 
pyrimido- [4,5-d]pyrimidines, a class of annulated 
uracils, have been found to possess a wide range of 
biological activity. They act as bronchodilators8, 
antiallergic9, cardiotonic10, anti hypertensive11 and 
anticancer12 agents. Benzimidazole is an important 
nucleus that has been extensively used in medicinal 
chemistry, notable examples being the antihistaminic 
asterizole and the antiulcerative omeprazole13. 
Benzimidazoles are also known for their anti-
inflammatory14, antibiotic15, anthelmintic16, 
anticancer17, and antiviral activities18. 
Molecular hybridization is a relatively new concept 
in the field of drug design, and development involving 
the fusion of two or more pharmocophoric groups 
which have an inhibitory effect against the target 
disease. The newly designed structure can lead to 
compounds having improved affinity and efficacies 
than the parent compounds with reduced side effects, 
while retaining the desired characteristics of original 
template19-21. Prompted by these reports, and as a 
sequel to our interest in the synthesis of 
benzimidazole derivatives with potent biological 
activity22-25, we herein, report the synthesis and 
antimicrobial activity of benzo[4,5]imidazo[1,2-a] 
pyrimido[4,5-d]pyrimidine derivatives. 
 
Results and Discussion  
The synthesis of title compounds was 
accomplished by synthetic sequence shown in 
Scheme I. The three-component reaction of 2-amino 
benzimidazole 1, substituted aromatic aldehyde 2, and 
malononitrile 3 in presence of p-toluene  
sulphonic acid (PTSA), a Lewis acid catalyst, in 
ethanol furnished novel 2-amino-4-aryl-4, 
10-dihydrobenzo[4,5]imidazo[1,2-a]pyrimidine-3-
carbonitriles 4 in good yields. This reaction is similar 
to the reaction reported earlier in the literature26. 
Compounds 4 on treatment with formamide and urea 
separately in glacial acetic acid gave the 5-aryl-5,11-
dihydro benzo[4,5]imidazo[1,2-a]pyrimido[4,5-d] 
pyrimidine-4-amines 5, and 5-aryl-5,11-dihydro 
benzo[4,5]imidazo[1,2-a]pyrimido[4,5-d] pyrimidine-
2, 4-diamines 6. This reaction is in accordance with 
earlier report on pyrimidine derivatives27. 
Twenty four new derivatives were reported. The 
structures of newly synthesized compounds 4a-h, 5a-
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h, and 6a-h were confirmed by analytical and spectral 
data (IR, 1H NMR, 13C NMR and MS). 
IR spectrum of 4a exhibited absorption bands at 
3435, 3415 cm-1 due to NH2, where as CN absorption 
band was shown at 2215 cm-1. In 1H NMR spectrum of 
4a pyrimidine ring CH proton appeared as a sharp 
singlet at δ 5.13, NH2 protons appeared at δ 8.25, 
which are D2O exchangeable, whereas imidazole ring 
NH displayed as a singlet at δ 10.25, which is also D2O 
exchangeable. Aromatic protons appeared as a 
complex multiplet between δ 7.00-7.83. 13C NMR 
spectrum of 4a exhibited CN and Ar-CH carbon 
signals at δ 83.25 and 52.54 confirming cyclization. 
The mass spectrum of 4a displayed the molecular ion 
[M+H]+ peak at m/z 288. In IR spectrum of 5a NH2 
absorption bands appeared at 3388, 3305 cm-1. 1H 
NMR spectrum of 5a exhibited a singlet at δ 8.50 due 
to the newly formed pyrimidine ring proton confirming 
cyclization. Rest of the signals are in agreement with 
the proposed structure. 13C NMR spectrum of 5a 
displayed –N=CH-N= carbon at δ 166.04. The mass 
spectrum of 5a exhibited the molecular ion [M+H]+ 
peak at m/z 315, which is in agreement with assigned 
structure. Similarly, The IR, 1HNMR, and 13C NMR 
spectra of 6 are very well in agreement with the 
proposed structure. The mass spectrum of 6a displayed 
molecular ion [M+H]+ peak at m/z 330. Data from the 
elemental analyses further confirmed the assigned 
structure of 4a-h, 5a-h, and 6a-h. 
 
Antimicrobial activity 
Antibacterial activity 
The newly synthesized 5-aryl-5,11-
dihydrobenzo[4,5]imidazo[1,2-a]pyrimido[4,5-
d]pyrimidin-4-amines 5a-h, 5-aryl-5,11-
dihydrobenzo[4,5]imidazo[1,2-a]pyrimido[4,5-
d]pyrimidine-2,4-diamines 6a-h were evaluated for their 
in vitro antibacterial activity against Gram-positive 
bacteria viz., Bacillus subtilis (MTCC 441), Bacillus 
sphaericus (MTCC 511) and Staphylococcus aureus 
(MTCC 96) and Gram-negative bacteria viz., 
Pseudomonas aeruginosa (MTCC 741), Klobsinella 
 
 
Scheme I 
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aerogenes (MTCC 39) and Chromobacterium 
violaceum (MTCC 2656) at 100 µg/ml concentration. 
The in vitro antibacterial activity of the tested 
compounds was assessed by minimum inhibitory 
concentration (MIC) using broth dilution method28. 
Ciprofloxacin was used as standard drug for 
comparison.  
The antibacterial activity results showed that 
compounds 5a-h and 6a-h displayed a better activity 
and were more active than the standard drug 
Ciprofloxacin (Table I and Table II). The activity was 
expressed in terms of minimum inhibitory 
concentration (MIC). The compounds 5e, 5f and 5g, 
6e, 6f and 6g are highly active, because the activity is 
considerably affected by the presence of methyl, 
methoxy and dimethyl amino as substituents on 
benzene ring. Compounds 5b, 5c and 5h, 6b, 6c and 
6h carrying chloro and bromo substitutions on 
benzene ring did not exhibit much activity. 
Compounds 5a and 6a showed least activity, because 
they did not have any substituent on the benzene ring. 
However, the degree of inhibition varied both with the 
test compound as well as with the bacteria used in the 
present investigation. 
In conclusion, the antibacterial activity of 
compounds 5f and 5g, 6f and 6g is promising 
compared to standard drug Ciprofloxacin, and they 
can be exploited for formulation of bacteriocides after 
further study. 
 
Antifungal activity 
The newly synthesized 5-aryl-5,11-
dihydrobenzo[4,5]imidazo[1,2-a]pyrimido[4,5-
d]pyrimidin-4-amines 5a-h and 5-aryl-5,11-
dihydrobenzo[4,5]imidazo[1,2-a]pyrimido[4,5-
d]pyrimidine-2,4-diamines 6a-h were also evaluated for 
Table I — Antibacterial activity of 5-phenyl-5,11-dihydrobenzo[4,5]imidazo[1,2-a]pyrimido[4,5-d]pyrimidin-4-amines. 5a-h 
Compd 
 Minimum Inhibitory Concentration in µg/ml (MIC) 
Ar 
Gram + ve bacteria Gram –ve bacteria 
B.subtilis B.sphaericus S.aureus P.aeruginosa K.aerogenes C.violaceum 
5a C6H5 17 19 19 18 17 17 
5b 2-ClC6H4 19 20 18 20 18 17 
5c 2-BrC6H4 16 13 12 16 16 17 
5d 2-OHC6H4 18 14 14 13 17 16 
5e 4-CH3C6H4 8 7 7 8 7 8 
5f 4-OCH3C6H4 7 8 8 9 9 8 
5g 4-N(CH3)2C6H4 6 7 8 8 7 6 
5h 2,4-Cl2C6H3 15 17 16 14 16 15 
Ciprofloxacin --- 20 22 26 25 20 22 
Negative control (acetone) – No activity 
Values are indicated in µg/mL 
 
Table II — Antibacterial activity of 5-phenyl-5,11-dihydrobenzo[4,5]imidazo[1,2-a]pyrimido[4,5-d]pyrimidine-2,4-diamines 6a-h 
Compd 
 Minimum Inhibitory Concentration in µg/ml (MIC) 
Ar 
Gram + ve bacteria Gram –ve bacteria 
B.subtilis B.sphaericus S.aureus P.aeruginosa K.aerogenes C.violaceum 
6a C6H5 17 17 19 20 19 19 
6b 2-ClC6H4 17 20 19 20 18 17 
6c 2-BrC6H4 16 13 13 16 15 16 
6d 2-OHC6H4 18 16 14 13 16 17 
6e 4-CH3C6H4 8 7 6 7 8 6 
6f 4-OCH3C6H4 8 6 7 8 9 8 
6g 4-N(CH3)2C6H4 8 7 6 8 8 9 
6h 2,4-Cl2C6H3 15 17 16 14 18 15 
Ciprofloxacin --- 20 22 26 25 20 22 
Negative control (acetone) – No activity 
Values are indicated in µg/mL 
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their antifungal activity against Fusarium oxysporum, 
Verticillium dahliae, Alternaria solani, Rhizoctonia 
solani, Colletotrichum capsici and Pythium 
aphanidermatum in acetone by agar cup  
bioassay method29, using Fluconazole as the standard 
drug.  
Antifungal activity data (Table III and Table IV) 
revealed that compounds 5a-h and 6a-h are highly 
toxic towards all the fungi under investigation. 
Compounds 5e, 5f and 5g, 6e, 6f and 6g exhibited 
high antifungal activity by inhibiting the growth  
of fungi to a remarkable extent, when compared  
to the standard drug Fluconazole, which may be due 
to the presence of methyl, methoxy and 
dimethylamino substituents on the benzene ring. 
Compounds 5a and 6a showed low activity. 
Compounds 5b, 5c and 5d are moderately active. 
However, the degree of spore germination inhibition 
varied with the test compound as well as with the 
fungi under investigation. It is noteworthy that 
compounds 5f and 5g and 6f, 6g showed better 
activity, when compared with the standard drug 
Fluconazole, hence, they may be exploited for 
control of wilt diseases of different crops as 
fungicides after further studies.  
In conclusion, the results revealed that compounds 
5g and 6g are highly toxic towards the fungi under 
investigation and they are lethal even at 100 µg/mL 
concentration in comparison with standard 
Fluconazole at the same concentration, and may be 
exploited for control of wilt diseases of different 
crops as fungicides after detailed study. 
 
Experimental Section 
All the melting points were determined on a  
Fisher-Johns melting point apparatus and are 
uncorrected. Analytical TLC was performed on 
Merck precoated 60 F254 silica gel plates. 
Visualization was carried out by exposure to  
iodine vapour. IR spectra (KBr pellet) were recorded 
on a Perkin-Elmer BX series FT-IR spectrometer.  
1H NMR spectra were recorded on a Varian  
Gemini 300 MHz spectrometer. 13C NMR spectra 
were recorded on a Bruker 75 MHz spectrometer. 
Chemical shift values are given in δ ppm  
with tetramethyl silane as an internal standard. ESI 
Table III — Antifungal activity of 5-phenyl-5,11-dihydrobenzo[4,5]imidazo[1,2-a]pyrimido[4,5-d]pyrimidin-4-amines. 5a-h 
Compd  Minimum inhibitory Concentration in µg/mL(MIC)  
Ar F.oxysporum V. dahliae A. solani R. solani C. capsici P. aphanidermatum 
5a C6H5 13 15 11 12 15 16 
5b 2-ClC6H4 16 15 14 17 19 20 
5c 2-BrC6H4 15 19 18 15 18 17 
5d 2-OHC6H4 17 16 18 12 18 20 
5e 4-CH3C6H4 8 7 7 9 8 9 
5f 4-OCH3C6H4 8 7 8 9 8 9 
5g 4-N(CH3)2C6H4 6 7 6 8 9 6 
5h 2,4-Cl2C6H3 11 12 13 14 13 14 
Fluconazole --- 16 16 20 16 18 22 
Negative control (acetone) – No activity. 
 
 
Table IV — Antifungal activity of 5-phenyl-5,11-dihydrobenzo[4,5]imidazo[1,2-a]pyrimido[4,5-d]pyrimidine-2,4-diamines. 6a-h 
Compd  Minimum inhibitory concentration in µg/mL(MIC)  
Ar F.oxysporum V. dahliae A. solani R. solani C. capsici P. aphanidermatum 
6a C6H5 12 14 12 12 14 15 
6b 2-ClC6H4 16 14 15 16 18 20 
6c 2-BrC6H4 14 18 18 16 17 17 
6d 2-OHC6H4 10 11 14 12 12 13 
6e 4-CH3C6H4 8 8 7 8 8 9 
6f 4-OCH3C6H4 8 6 9 8 8 8 
6g 4-N(CH3)2C6H4 8 7 8 6 9 8 
6h 2,4-Cl2C6H3 10 11 14 12 12 13 
Fluconazole -- 16 16 20 16 18 22 
Negative control (acetone) – No activity. 
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Mass spectra were recorded on a Agilent LC-MSD 
mass spectrometer. Elemental analyses were 
performed on a Carlo Erba 106 and Perkin-Elmer 
model 240 analyzers. 
General procedure for the synthesis of 2-amino-4-
aryl-4,10-dihydrobenzo[4,5]imidazo[1,2-
a]pyrimidine-3-carbonitriles, 4a-h  
To a vigorously stirred aromatic aldehyde 2 
(1mmol), and malononitrile 3 (1mmol), 2-amino 
benzimidazole in ethanol was added and contents 
were refluxed while stirring for 4 h. The termination 
of the reaction was monitored by TLC. After 
completion of the reaction, the reaction was poured on 
to crushed ice, The separated solid was filtered, and 
purified by recrystallization from benzene-ethyl 
acetate to obtain pure compounds (4a-h). 
2-Amino-4-phenyl-4,10-
dihydrobenzo[4,5]imidazo[1,2-a]pyrimidine-3-
carbonitrile, 4a: Orange solid, yield 67%, m.p. 175-
77oC, IR (KBr): 3435, 3415 (NH2), 2215 (CN) cm-1; 
1H NMR (300 MHz, CDCl3): δ 5.13 (s, 1H, CH), 
7.00-7.83 (m, 9H), 8.25 (s, 2H, NH2, D2O 
exchangeable), 10.25 (s,1NH, D2O exchangeable); 13C 
NMR (75MHz, CDCl3): δ 52.54, 83.25, 117.21, 
120.23, 123.56, 125.37, 128.31, 131.28, 133.56, 
135.21, 137.23, 138.00, 140.01, 142.20, 146.21, 
168.21, 169.31; ESI-MS: m/z 288 [M+H]+ . 
Anal.cacld for C17H13N5: C, 71.08; H, 4.52; N, 24.39 
% Found: C, 71.05; H, 4.55; N, 24.43%. 
2-Amino-4-(2-chlorophenyl)-4,10-
dihydrobenzo[4,5]imidazo[1,2-a]pyrimidine-3-
carbonitrile, 4b: Pale yellow solid, yield 70%, m.p. 
180-82oC, IR (KBr): 3445, 3425 (NH2), 2225 (CN) 
cm-1; 1H NMR (300 MHz, CDCl3): δ 5.16 (s, 1H, 
CH), 7.05-7.89 (m, 8H), 8.28 (s, 2H, NH2, D2O 
exchangeable), 10.28 (s,1NH, D2O exchangeable); 13C 
NMR (75MHz, CDCl3): δ 53.14, 84.27, 118.25, 
121.23, 124.66, 126.39, 128.31, 132.23, 134.59, 
136.21, 138.50, 139.09, 141.11, 142.29, 147.28, 
169.21, 170.30; ESI-MS: m/z 322 [M+H]+ . 
Anal.cacld for C17H12N5Cl: C, 63.55; H, 3.73;  
N, 21.80 % Found: C, 63.51; H, 3.76; N, 21.84 %. 
2-Amino-4-(2-bromophenyl)-4,10-
dihydrobenzo[4,5]imidazo[1,2-a]pyrimidine-3-
carbonitrile, 4c: Brown solid, yield 73%, m.p.220-
22oC. IR (KBr): 3443, 3423 (NH2), 2222 (CN) cm-1; 
1H NMR (300 MHz, CDCl3): δ 5.15 (s, 1H, CH), 
7.03-7.85 (m, 8H), 8.26 (s, 2H, NH2, D2O 
exchangeable), 10.24 (s,1NH, D2O exchangeable); 13C 
NMR (75MHz, CDCl3): δ 52.89, 85.29, 117.79, 
122.29, 123.79, 127.41, 127.36, 133.29, 134.568, 
135.20, 139.76, 139.99, 140.51, 143.39, 146.08, 
168.11, 169.20; ESI-MS: m/z 366 [M+H]+ . 
Anal.cacld for C17H12N5Br: C, 55.89; H, 3.28;  
N, 19.17 % Found: C, 55.92; H, 3.24; N, 19.21 %. 
2-Amino-4-(2-hydroxyphenyl)-4,10-
dihydrobenzo[4,5]imidazo[1,2-a]pyrimidine-3-
carbonitrile, 4d: yellow solid, yield 75%, m.p. 200-
02oC, IR (KBr): 3454 (OH), 3447, 3426 (NH2), 2227 
(CN) cm-1; 1H NMR (300 MHz, CDCl3): δ 5.17 (s, 
1H, CH), 7.10-7.99 (m, 8H), 8.30 (s, 2H, NH2, D2O 
exchangeable), 8.56 (s, 1H, OH, D2O exchangeable), 
10.29 (s,1NH, D2O exchangeable); 13C NMR 
(75MHz, CDCl3): δ 55.34, 86.27, 120.15, 121.23, 
124.69, 127.39, 127.99, 133.53, 135.39, 136.29, 
139.30, 139.89, 142.01, 143.19, 147.55, 168.11, 
171.00; ESI-MS: m/z 304 [M+H]+ . Anal.cacld for 
C17H13N5O: C, 63.32; H, 4.29; N, 23.10 % Found: C, 
63.35; H, 4.26; N, 23.14 %. 
2-Amino-4-(p-tolyl)-4,10-
dihydrobenzo[4,5]imidazo[1,2-a]pyrimidine-3-
carbonitrile, 4e: Pale yellow solid, yield 78%, m.p. 
195-97oC, IR (KBr): 3443, 3423 (NH2), 2223 (CN) 
cm-1; 1H NMR (300 MHz, CDCl3): δ 2.35 (s, 3H, 
CH3), 5.17 (s, 1H, CH), 7.06-7.92 (m, 8H), 8.25  
(s, 2H, NH2, D2O exchangeable), 10.26 (s,1NH, D2O 
exchangeable); 13C NMR (75MHz, CDCl3): δ 23.45, 
54.44, 85.37, 121.25, 122.25, 123.69, 128.59, 126.90, 
134.53, 136.33, 137.19, 139.50, 140.09, 143.01, 
143.59, 147.75, 168.19, 170.05; ESI-MS: m/z 302 
[M+H]+ . Anal.cacld for C18H15N5: C, 71.76; H, 4.98; 
N, 23.25 % Found: 71.72; H, 4.95; N, 23.28 %. 
2-Amino-4-(4-methoxyphenyl)-4,10-
dihydrobenzo[4,5]imidazo[1,2-a]pyrimidine-3-
carbonitrile, 4f: yellow solid, yield 85%, m.p. 207-
09oC, IR (KBr): 3446, 3427 (NH2), 2228 (CN) cm-1; 
1H NMR (300 MHz, CDCl3): δ 3.78 (s, 3H, OCH3), 
5.19 (s, 1H, CH), 7.09-7.95 (m, 8H), 8.28 (s, 2H, 
NH2, D2O exchangeable), 10.28 (s,1NH, D2O 
exchangeable); 13C NMR (75MHz, CDCl3): δ 54.44, 
64.48, 85.39, 120.29, 121.35, 122.69, 124.79, 127.94, 
135.59, 138.33, 138.89, 139.59, 141.19, 144.21, 
144.89, 147.79, 169.19, 171.03; ESI-MS: m/z 319 
[M+H]+ . Anal.cacld for C18H15N5O: C, 67.92; H, 
4.71; N, 22.01 % Found: 67.95; H, 4.75; N, 22.02 %. 
2-Amino-4-(4-(dimethylamino)phenyl)-4,10-
dihydrobenzo[4,5]imidazo[1,2-a]pyrimidine-3-
carbonitrile, 4g: yellow solid, yield 87%, m.p. 213-
15oC, IR (KBr): 3446, 3428 (NH2), 2230 (CN) cm-1; 
1H NMR (300 MHz, CDCl3): δ 2.80 (s, 6H, N(CH3)2), 
5.21 (s, 1H, CH), 7.10-7.90 (m, 8H), 8.30 (s, 2H, 
NH2, D2O exchangeable), 10.25 (s,1NH, D2O 
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exchangeable); 13C NMR (75MHz, CDCl3): δ 48.32, 
51.79, 54.49, 86.37, 121.39, 122.45, 123.60, 125.77, 
128.94, 136.60, 137.03, 138.39, 138.89, 140.19, 
145.11, 146.39, 147.89, 168.12, 170.53; ESI-MS: m/z 
331 [M+H]+ . Anal.cacld for C19H18N6: C, 69.09; H, 
5.45; N, 25.45 % Found: 69.05; H, 5.48; N, 25.43 %. 
2-Amino-4-(2,4-dichlorophenyl)-4,10-
dihydrobenzo[4,5]imidazo[1,2-a]pyrimidine-3-
carbonitrile, 4h: Pale yellow solid, yield 68%, m.p. 
188-90oC, IR (KBr): 3448, 3429 (NH2), 2230 (CN) 
cm-1; 1H NMR (300 MHz, CDCl3): δ 5.21 (s, 1H, 
CH), 7.05-7.95 (m, 7H), 8.35 (s, 2H, NH2, D2O 
exchangeable), 10.39 (s,1NH, D2O exchangeable); 13C 
NMR (75MHz, CDCl3): δ 54.24, 87.27, 119.35, 
122.33, 124.69, 127.69, 129.30, 131.93, 135.09, 
137.11, 138.70, 139.89, 142.11, 143.34, 147.29, 
168.61, 171.10; ESI-MS: m/z 356 [M+H]+. Anal.cacld 
for: C, 57.46; H, 3.09; N, 19.71 % Found: C, 57.43; 
H, 3.13; N, 19.73 %. 
 
General procedure for the synthesis of 5-phenyl-
5,11-dihydrobenzo[4,5]imidazo[1,2-
a]pyrimido[4,5-d]pyrimidin-4-amines, 5a-h 
A mixture of compound 4 (1.06 g, 5 mmol), and 
formamide (10 mL) was refluxed for 5 h. After the 
completion of the reaction (monitored by TLC) the 
reaction mixture was cooled, separated solid is 
filtered off, washed with methanol, and recrystallized 
from ethyl acetate to give pure compounds (5a-h).  
 
5-Phenyl-5,11-dihydrobenzo[4,5]imidazo[1,2-
a]pyrimido[4,5-d]pyrimidin-4-amine, 5a: Orange 
solid, yield 69%, m.p. 225-27oC, IR (KBr): 3388, 
3305 (NH2), cm-1; 1H NMR (300 MHz, CDCl3): δ 
5.19 (s, 1H, CH), 7.00-7.98 (m, 9H), 7.95 (s, 2H, 
NH2, D2O exchangeable), 8.50 ( s, 1H, N=CH), 10.20 
(s,1NH, D2O exchangeable); 13C NMR (75MHz, 
CDCl3): δ 44.52, 109.34, 115.43, 117.54, 118.64, 
120.02, 127.86, 128.99, 129.03, 130.02, 130.95, 
131.23, 134.84, 143.94, 156.84, 159.94, 164.93, 166. 
04; ESI-MS: m/z 315 [M+H]+ . Anal.cacld for 
C18H14N6: C, 68.78; H, 4.45; N, 26.75 % Found:  
C, 68.75; H, 4.43; N, 26.78 %. 
 
5-(2-Chlorophenyl)-5,11-
dihydrobenzo[4,5]imidazo[1,2-a]pyrimido[4,5-
d]pyrimidin-4-amine, 5b: Pale Yellow solid, yield 
65%, m.p. 234-36oC, IR (KBr): 3396, 3315 (NH2), 
cm-1; 1H NMR (300 MHz, CDCl3): δ 5.25 (s, 1H, 
CH), 7.06-8.02 (m, 8H), 7.99 (s, 2H, NH2, D2O 
exchangeable), 8.55 (s, 1H, N=CH), 10.25 (s, 1NH, 
D2O exchangeable); 13C NMR (75MHz, CDCl3):  
δ 45.58, 110.24, 116.73, 118.44, 118.94, 121.02, 
128.02, 129.09, 129.95, 131.09, 131.95, 132.03, 
134.84, 144.34, 157.80, 160.94, 165.91, 167. 01; ESI-
MS: m/z 349 [M+H]+ . Anal.cacld for C18H13N6Cl:  
C, 62.06; H, 3.73; N, 24.13 % Found: C, 62.03;  
H, 3.76; N, 24.10 %. 
5-(2-Bromophenyl)-5,11-
dihydrobenzo[4,5]imidazo[1,2-a]pyrimido[4,5-
d]pyrimidin-4-amine, 5c: Brown solid, yield 60%, 
m.p. 244-46oC, IR (KBr): 3394, 3313 (NH2), cm-1; 1H 
NMR (300 MHz, CDCl3): δ 5.22 (s, 1H, CH), 7.06-
8.00 (m, 8H), 7.96 (s, 2H, NH2, D2O exchangeable), 
8.53 (s, 1H, N=CH), 10.22 (s, 1NH, D2O 
exchangeable); 13C NMR (75MHz, CDCl3): δ 44.59, 
109.24, 115.79, 117.40, 117.90, 120.02, 127.76, 
128.34, 128.95, 130.09, 131.05, 132.03, 133.80, 
143.24, 156.82, 160.35, 164.31, 166.67; ESI-MS: m/z 
393 [M+H]+ . Anal.cacld for C18H13N6Br: C, 55.10;  
H, 3.31; N, 21.42 % Found: C, 55.14; H, 3.35; N, 
21.46%. 
2-(4-Amino-5,11-dihydrobenzo[4,5]imidazo[1,2-
a]pyrimido[4,5-d]pyrimidin-5-yl)phenol, 5d: Pale 
Yellow solid, yield 75%, m.p. 239-41oC, IR (KBr): 
3456 (OH), 3395, 3316 (NH2),cm-1; 1H NMR  
(300 MHz, CDCl3): δ 5.26 (s, 1H, CH), 7.10-8.02  
(m, 8H), 7.98 (s, 2H, NH2, D2O exchangeable), 8.53 
(s, 1H, N=CH), 8.59 (s, 1H, OH, D2O exchangeable), 
10.25 (s, 1NH, D2O exchangeable); 13C NMR 
(75MHz, CDCl3): δ 45.29, 110.14, 116.39, 118.20, 
118.98, 121.02, 128.72, 129.34, 130.00, 130.89, 
131.65, 132.03, 134.88, 144.24, 157.42, 161.55, 
165.31, 167.17; ESI-MS: m/z 331 [M+H]+. Anal.cacld 
for C18H14N6O: C, 65.45; H, 4.24; N, 25.45 % Found: 
C, 65.49; H, 4.22; N, 25.47%. 
5-(p-Tolyl)-5,11-dihydrobenzo[4,5]imidazo[1,2-
a]pyrimido[4,5-d]pyrimidin-4-amine, 5e: Pale 
Yellow solid, yield 78%, m.p. 232-34oC, IR (KBr): 
3393, 3315 (NH2), cm-1; 1H NMR (300 MHz, CDCl3): 
δ 2.45 (s, 3H, CH3), 5.24 (s, 1H, CH), 7.04-8.00  
(m, 8H), 7.96 (s, 2H, NH2, D2O exchangeable), 8.50 
(s, 1H, N=CH), 10.22 (s, 1NH, D2O exchangeable); 
13C NMR (75MHz, CDCl3): δ 24.12, 44.09, 109.14, 
115.39, 117.10, 117.98, 120.92, 127.72, 128.34, 
129.12,130.89, 131.65, 131.98, 133.48, 143.24, 
156.40, 160.65, 164.21, 166.27; ESI-MS: m/z 329 
[M+H]+ . Anal.cacld for C19H16N6: C, 69.51; H, 4.87; 
N, 25.60 % Found: C, 69.54; H, 4.86; N, 25.63%. 
5-(4-Methoxyphenyl)-5,11-
dihydrobenzo[4,5]imidazo[1,2-a]pyrimido[4,5-
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d]pyrimidin-4-amine, 5f: Pale Yellow solid, yield 
80%, m.p. 250-52oC, IR (KBr): 3397, 3319 (NH2), 
cm-1; 1H NMR (300 MHz, CDCl3): δ 3.68 (s, 3H, 
OCH3), 5.29 (s, 1H, CH), 7.09-8.05 (m, 8H), 7.98 (s, 
2H, NH2, D2O exchangeable), 8.52 (s, 1H, N=CH), 
10.24 (s, 1NH, D2O exchangeable); 13C NMR 
(75MHz, CDCl3): δ 45.19, 64.47, 110.24, 116.45, 
118.10, 118.98, 121.42, 128.32, 129.04, 129.96, 
131.29, 132.25, 132.98, 134.48, 144.14, 157.40, 
161.75, 165.31, 167.17; ESI-MS: m/z 345 [M+H]+ . 
Anal.cacld for C19H16N6O: C, 66.27; H, 4.65; N, 
24.41 % Found: C, 66.24; H, 4.68; N, 24.43 %. 
5-(4-(Dimethylamino)phenyl)-5,11-
dihydrobenzo[4,5]imidazo[1,2-a]pyrimido[4,5-
d]pyrimidin-4-amine, 5g: Pale Yellow solid, yield 
81%, m.p. 256-58oC, IR (KBr): 3396, 3318 (NH2), 
cm-1; 1H NMR (300 MHz, CDCl3): δ 2.45 (s, 6H, 
(NH3)2), 5.28 (s, 1H, CH), 7.05-8.01 (m, 8H), 7.98 (s, 
2H, NH2, D2O exchangeable), 8.50 (s, 1H, N=CH), 
10.22 (s, 1NH, D2O exchangeable); 13C NMR 
(75MHz, CDCl3): δ 44.29, 48.51, 51.23, 63.47, 
109.24, 115.25, 117.11, 117.98, 120.62, 127.32, 
128.01, 128.96, 130.24, 131.15, 132.35, 133.28, 
143.24, 156.30, 160.25, 164.21, 166.17; ESI-MS: m/z 
358 [M+H]+ . Anal.cacld for C20H19N7: C, 67.22;  
H, 5.32; N, 27.45 % Found: C, 67.20; H, 5.35;  
N, 27.43 %. 
5-(2,4-Dichlorophenyl)-5,11-
dihydrobenzo[4,5]imidazo[1,2-a]pyrimido[4,5-
d]pyrimidin-4-amine, 5h: Pale Yellow solid, yield 
64%, m.p. 249-51oC, IR (KBr): 3398, 3320 (NH2), 
cm-1; 1H NMR (300 MHz, CDCl3): δ 5.27 (s, 1H, 
CH), 7.06-8.10 (m, 7H), 7.99 (s, 2H, NH2, D2O 
exchangeable), 8.59 (s, 1H, N=CH), 10.29 (s, 1NH, 
D2O exchangeable); 13C NMR (75MHz, CDCl3):  
δ 46.38, 111.14, 117.13, 119.24, 119.99, 122.02, 
129.12, 129.89, 130.25, 132.09, 132.95, 133.03, 
134.84, 145.34, 156.86, 161.96, 164.91, 168.06;  
ESI-MS: m/z 383 [M+H]+ . Anal.cacld for 
C18H12N6Cl2: C, 56.54; H, 3.14; N, 21.98 % Found: C, 
56.56; H, 3.12; N, 21.95 % 
 
General procedure for the Synthesis of phenyl-
5,11-dihydrobenzo[4,5]imidazo[1,2-
a]pyrimido[4,5-d]pyrimidine-2,4-diamines, 6a-h 
A mixture of compound 4 (1.06 g, 5 mmol), and 
urea (0.3 g, 5 mmol) was refluxed in glacial acetic 
acid and hydrochloric acid (10 mL; 3:1) for 10 h. 
After being cooled, the precipitated solid was filtered 
off, and recrystallized from ethanol to give 6a-h in 
good yield. 
5-Phenyl-5,11-dihydrobenzo[4,5]imidazo[1,2-
a]pyrimido[4,5-d]pyrimidine-2,4-diamine 6a: Pale 
Yellow solid, yield 68%, m.p. 258-60oC, IR (KBr): 
3410 (2NH2), cm-1; 1H NMR (300 MHz, CDCl3):  
δ 5.25 (s, 1H, CH), 7.01-7.95 (m, 9H), 7.43 (s, 2H, 
NH2, D2O exchangeable), 7.91 (s, 2H, NH2,  
D2O exchangeable), 10.21 (s, 1NH, D2O 
exchangeable); 13C NMR (75MHz, CDCl3): δ 45.59, 
110.34, 116.53, 118.24, 119.34, 121.12, 128.86, 
129.32, 130.03, 131.09, 131.25, 132.35, 135.84, 
144.25, 159.96, 162.34, 164.96, 166.04; ESI-MS:  
m/z 330 [M+H]+ . Anal.cacld for C18H15N7: C, 65.65; 
H, 4.55; N, 29.78 % Found: C, 65.63; H, 4.52; N, 
29.75 %. 
5-(2-Chlorophenyl)-5,11-
dihydrobenzo[4,5]imidazo[1,2-a]pyrimido[4,5-
d]pyrimidine-2,4-diamine 6b: Pale Yellow solid, 
yield 65%, m.p. 267-69oC, IR (KBr): 3415 (2NH2), 
cm-1; 1H NMR (300 MHz, CDCl3): δ 5.28 (s, 1H, 
CH), 7.01-7.99 (m, 8H), 7.46 (s, 2H, NH2, D2O 
exchangeable), 7.95 (s, 2H, NH2, D2O exchangeable), 
10.26 (s, 1NH, D2O exchangeable); 13C NMR 
(75MHz, CDCl3): δ 46.79, 111.44, 117.53, 118.84, 
120.04, 122.22, 129.02, 129.89, 131.03, 131.99, 
132.15, 133.45, 136.84, 145.45, 158.96, 163.34, 
164.99, 167.14; ESI-MS: m/z 364 [M+H]+ . 
Anal.cacld for C18H14N7 Cl: C, 59.50; H, 3.85;  
N, 26.99 % Found: C, 59.54; H, 3.82; N, 26.97%. 
 
5-(2-Bromophenyl)-5,11-
dihydrobenzo[4,5]imidazo[1,2-a]pyrimido[4,5-
d]pyrimidine-2,4-diamine 
6c: Brown solid, yield 60%, m.p. 289-91oC, IR 
(KBr): 3409 (2NH2), cm-1; 1H NMR (300 MHz, 
CDCl3): δ 5.22 (s, 1H, CH), 6.98-7.90 (m, 8H), 7.42 
(s, 2H, NH2, D2O exchangeable), 7.90 (s, 2H, NH2, 
D2O exchangeable), 10.20 (s, 1NH, D2O 
exchangeable); 13C NMR (75MHz, CDCl3): δ 45.19, 
110.44, 116.43, 117.84, 120.04, 121.42, 128.12, 
128.84, 130.13, 130.99, 131.25, 132.85, 135.84, 
144.45, 157.96, 162.64, 163.95, 166.24; ESI-MS: m/z 
408 [M+H]+ . Anal.cacld for C18H14N7 Br: C, 53.07; 
H, 3.43; N, 24.07 % Found: C, 53.05; H, 3.40; N, 
24.09 %. 
 
2-(2,4-Diamino-5,11-
dihydrobenzo[4,5]imidazo[1,2-a]pyrimido[4,5-
d]pyrimidin-5-yl)phenol 
6d: Pale Yellow solid, yield 73%, m.p. 255-57oC, 
IR (KBr): 3417 (2NH2), 3436 (OH) cm-1; 1H NMR 
(300 MHz, CDCl3): δ 5.29 (s, 1H, CH), 7.01-7.99  
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(m, 8H), 7.43 (s, 2H, NH2, D2O exchangeable), 7.91 
(s, 2H, NH2, D2O exchangeable), 8.55 (s, 1H, OH, 
D2O exchangeable), 10.22 (s, 1NH, D2O 
exchangeable); 13C NMR (75MHz, CDCl3): δ 46.49, 
111.24, 117.63, 119.64, 120.34, 121.78, 129.36, 
130.02, 130.93, 132.09, 132.85, 133.01, 136.84, 
145.05, 159.96, 163.14, 165.36, 166.04; ESI-MS: m/z 
364 [M+H]+ . Anal.cacld for C18H15N7 O: C, 59.50;  
H, 3.85; N, 26.99 % Found: C, 59.54; H, 3.82;  
N, 26.97%. 
5-(p-Tolyl)-5,11-dihydrobenzo[4,5]imidazo[1,2-
a]pyrimido[4,5-d]pyrimidine-2,4-diamine 6e: Pale 
Yellow solid, yield 78%, m.p. 284-86oC, IR (KBr): 
3416 (2NH2), cm-1; 1H NMR (300 MHz, CDCl3): 
δ2.35 (s.3H, CH3), 5.27 (s, 1H, CH), 6.99-7.97  
(m, 8H), 7.46 (s, 2H, NH2, D2O exchangeable), 7.99 
(s, 2H, NH2, D2O exchangeable), 10.26 (s, 1NH, D2O 
exchangeable); 13C NMR (75MHz, CDCl3): δ 24.65, 
46.49, 111.34, 117.83, 118.56, 120.24, 122.17, 
128.97, 130.02, 131.13, 131.89, 132.45, 133.35, 
136.44, 145.35, 158.95, 163.44, 165.66, 166.54;  
ESI-MS: m/z 344 [M+H]+ . Anal.cacld for C19H17N7: 
C, 66.47; H, 4.95; N, 28.57 % Found: C, 66.43;  
H, 4.97; N, 28.53 %. 
5-(4-Methoxyphenyl)-5,11-
dihydrobenzo[4,5]imidazo[1,2-a]pyrimido[4,5-
d]pyrimidine-2,4-diamine 6f: Pale Yellow solid, 
yield 73%, m.p. 272-74oC, IR (KBr): 3412 (2NH2), 
cm-1; 1H NMR (300 MHz, CDCl3): δ 3.68 (s.3H, 
OCH3), 5.26 (s, 1H, CH), 6.98-7.90 (m, 8H), 7.45  
(s, 2H, NH2, D2O exchangeable), 7.94 (s, 2H, NH2, 
D2O exchangeable), 10.24 (s, 1NH, D2O 
exchangeable); 13C NMR (75MHz, CDCl3): δ 46.49, 
63.64, 112.24, 118.63, 119.26, 120.74, 123.07, 
129.37, 130.72, 132.18, 132.89, 133.25, 133.95, 
137.54, 146.25, 159.95, 164.34, 165.16, 167.24;  
ESI-MS: m/z 360 [M+H]+ . Anal.cacld for C19H17N7O: 
C, 63.50; H, 4.73; N, 27.29 % Found: C, 63.54; H, 
4.70; N, 27.26 %. 
5-(4-(Dimethylamino)phenyl)-5,11-
dihydrobenzo[4,5]imidazo[1,2-a]pyrimido[4,5-
d]pyrimidine-2,4-diamine 6g: Pale Yellow solid, 
yield 76%, m.p. 275-77oC, IR (KBr): 3418 (2NH2), 
cm-1; 1H NMR (300 MHz, CDCl3): δ 2.36 (s, 6H, 
N(CH3)2), 5.27 (s, 1H, CH), 7.01-7.93 (m, 8H), 7.45 
(s, 2H, NH2, D2O exchangeable), 7.96 (s, 2H, NH2, 
D2O exchangeable), 10.27 (s, 1NH, D2O 
exchangeable); 13C NMR (75MHz, CDCl3): δ 45.79, 
49.35, 52.23, 110.24, 116.53, 117.64, 121.04, 123.32, 
129.22, 130.49, 132.03, 132.99, 133.05, 134.45, 
137.80, 146.25, 159.96, 162.64, 163.90, 168.04;  
ESI-MS: m/z 373 [M+H]+ . Anal.cacld for C20H20N8:  
C, 64.51; H, 5.37; N, 30.10 % Found: C, 64.53; H,  
5.34; N, 30.12%. 
5-(2,4-Dichlorophenyl)-5,11-
dihydrobenzo[4,5]imidazo[1,2-a]pyrimido[4,5-
d]pyrimidine-2,4-diamine 6h: Pale Yellow solid, 
yield 63%, m.p. 288-90oC, IR (KBr): 3418 (2NH2), 
cm-1; 1H NMR (300 MHz, CDCl3): δ 5.29 (s, 1H, 
CH), 7.03-7.99 (m, 7H), 7.49 (s, 2H, NH2, D2O 
exchangeable), 7.98 (s, 2H, NH2, D2O exchangeable), 
10.29 (s, 1NH, D2O exchangeable); 13C NMR 
(75MHz, CDCl3): δ 45.89, 112.44, 118.63, 119.84, 
121.14, 122.62, 129.32, 130.19, 131.23, 131.99, 
133.35, 134.25, 137.84, 146.45, 159.96, 162.44, 
165.99, 166.74; ESI-MS: m/z 398 [M+H]+. Anal.cacld 
for C18H13N7Cl2: C, 54.40; H, 3.27; N, 24.68 % 
Found: C, 54.42; H, 3.25; N, 24.65 % 
 
Antibacterial activity 
The antibacterial activity was done by broth dilution 
method28 and expressed as minimum inhibitory 
concentration. The readymade nutrient broth medium 
(Himedia, 24 g) was suspended in distilled water (100 
mL) and heated to boiling until it dissolved completely. 
The medium and test tubes were autoclaved at pressure 
of 15 lb/ inc2 for 20 min. A set of sterilized test tubes 
with nutrient broth medium was capped with cotton 
plugs. The test compounds 5 and 6 were dissolved in 
suitable solvent (acetone) and concentration of 100 µg/ 
mL of test compound is added in the first test tube, 
which is serially diluted. A fixed volume of 0.5 mL 
overnight culture is added in all test tubes, and are 
incubated at 370C for 24 h. After 24 h, these tubes were 
measured for turbidity. Bacterial strains used for the 
present investigation, Bacillus subtilis (MTCC 441), 
Bacillus sphaericus (MTCC 511), Staphylococcus 
aureus (MTCC 96), Pseudomonas aeruginosa (MTCC 
741), Klobsiella aerogenes (MTCC 39) and 
Chromobacterium violaceum (MTCC 2656), were 
obtained from the Institute of Microbial Technology, 
Chandigarh. 
 
Antifungal activity 
The antifungal activity was done by using agar cup 
bioassay method29. The readymade potato dextrose agar 
(PDA) medium (Himedia, 39g) was suspended in 
distilled water (100 mL) and heated to boiling until it 
dissolved completely. The medium and petri-dishes 
were autoclaved at pressure of 15 lb/ inc2 for 20 min. 
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The medium was poured in to sterile petri-dishes under 
aseptic conditions in a laminar flow chamber. When the 
medium in the plates solidified, 0.5 mL of (week old) 
culture of test organism was inoculated and uniformly 
spread over the agar surface with a sterile L-shaped rod. 
Solutions were prepared by dissolving test compounds 
5/6 in acetone and different concentrations were made. 
Agar inoculated cups were scooped out with 6 mm 
sterile cork borer and the lids of the dishes were 
replaced. To each cup different concentrations of test 
solutions were added. Controls were maintained with 
acetone and Fluconazole. The treated and the controls 
were kept at room temperature for 72-96 h. The 
minimum inhibitory concentration (MIC) was recorded 
in µg/ml. Three to four replicates were maintained for 
each treatment. Fusarium oxysporum, Verticillium 
dahliae, Alternaria solani, Rhizoctonia solani, 
Colletotrichum capsici and Pythium aphanidermatum 
were used as fungal strains and procured from the 
Institute of Microbial Technology, Chandigarh. 
 
Conclusion 
In Conclusion, the synthesis of novel 
benzo[4,5]imidazo[1,2-a]pyrimido[4,5-d] pyrimidines 
has been achieved from readily accessible starting 
materials in good yields. The newly synthesized title 
compounds 5/6 have been evaluated for their in vitro 
antimicrobial activity. Compounds 5e, 5f, 5g and 6e, 
6f, 6g exhibited significant antimicrobial activity. 
Thus, they may be considered as future drug 
candidates and by doing a simple modification in the 
structure, a new potent analouge can be generated 
with desired activity and good efficacy.  
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